In this video, Fool.com analysts David Williamson and Max Macaluso discuss United Therapeutics and Discovery Laboratories' 15% intraday plunges. One received an FDA rejection, and the other had a familiar problem rear its ugly head. Watch and find out what this means for these stocks, their competitors, and investors.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.